Bacillus Subtilis: The Soil-Origin Spore Probiotic, Evidence-Reviewed

What is Bacillus subtilis?

Bacillus subtilis is a Gram-positive, rod-shaped, aerobic, spore-forming bacterium ubiquitous in soil, the rhizosphere of plants, and the human gut at low abundance. Its genome was the first Bacillus genome sequenced (1997) and it is one of the most studied model organisms in biology. The species also gives us natto via B. subtilis var. natto, and is the source of multiple industrial enzymes (subtilisin protease, amylase).

Three traits matter for its use as a probiotic:

• Endospore formation: survives stomach acid, ambient temperature, and most antibiotics in dormant form
• Immunomodulatory profile: animal and human studies show shifts in T-regulatory, IgA, and innate immune readouts
• Strain heterogeneity: non-pharmaceutical "soil-based" strains have been reported to carry transferable antibiotic resistance, so commercial use requires fully characterized strains

How spores work in the gut

Like B. coagulans, swallowed B. subtilis spores transit the stomach intact, germinate in the upper small intestine in response to amino acid and bile salt cues, then operate as vegetative cells through the small intestine and colon. They do not form a permanent colony — viable cells are largely cleared 5-10 days after stopping the supplement.

While in the gut, B. subtilis produces antimicrobial peptides (subtilin, surfactin) that inhibit some pathogens, secretes digestive enzymes that aid local protein and starch breakdown, and interacts with Peyer's patches to influence gut-associated lymphoid tissue (GALT) signaling. These effects are at the heart of its immune-adjunct claims.

Evidence-based benefits of B. subtilis

1. General GI regularity and bloating

Several RCTs of B. subtilis DE111 in healthy adults and adults with mild GI complaints show improvements in stool consistency, bowel-movement frequency, and self-reported bloating at 1 billion CFU/day for 4-6 weeks. A 2017 trial (Cuentas et al., n=22) showed reduced loose stools after a high-fat challenge.

2. Immune support in older adults

The CU1 strain has the best older-adult immune evidence: a 2015 RCT (Lefevre et al., n=100, mean age 71) showed reduced respiratory infection severity and modest IgA elevation across a 16-week intervention. A 2020 meta-analysis of B. subtilis probiotics in older adults found small but consistent reductions in upper-respiratory symptom days.

3. Multi-strain spore blends

Several products combine B. subtilis HU58 with B. coagulans, B. clausii, and B. licheniformis in 4-5 strain "spore blends" (e.g., MegaSporeBiotic). Two RCTs (McFarlin 2017, n=15; Kalman 2020) showed reductions in postprandial endotoxin response and improvements in subjective digestive comfort at 4 billion CFU/day. The clinical relevance of endotoxin biomarkers remains an active research question.

4. Athletic recovery and microbiome diversity (preliminary)

Small studies suggest B. subtilis spore blends modestly increase microbial diversity and reduce inflammatory biomarkers after exercise, but trial sizes are small and mechanistically focused. Not a primary indication.

5. Acute and chronic diarrhea (mixed evidence)

Some Eastern European clinical work supports B. subtilis use in acute diarrhea, but the products and strains used differ substantially from Western consumer probiotics. We don't extrapolate those data to U.S./EU products.

Key B. subtilis strains compared

Compare directly with Bacillus coagulans for IBS-specific use.

How much B. subtilis should you take?

• General gut/immune (DE111): 1 billion CFU/day for at least 4 weeks
• Older-adult immune (CU1): 2 billion CFU/day for 8-16 weeks
• Multi-strain spore blend (HU58 + others): 4 billion CFU/day, often with food

Safety, side effects, and immunocompromised hosts

Strain-characterized commercial B. subtilis (DE111, HU58, CU1) has GRAS status and an excellent RCT safety record. Common short-term effects:

• Mild flatulence or transient stool change in week 1
• Bloating that often improves with continued use

Immunocompromised, ICU, and central-line patients

As with all live-bacterial probiotics, avoid without specialist supervision in:

• Severe immunosuppression, neutropenia, transplant within 6 months
• Critically ill ICU patients with central venous catheters
• Severe acute pancreatitis

Rare cases of B. subtilis bacteremia have been reported in compromised hosts. Always use a fully characterized strain, not a "soil-based" generic.

Pregnancy and breastfeeding

Limited specific data; generally considered low-risk given long history in food (natto) but discuss with your obstetrician.

SIBO caveat

Spore probiotics are sometimes preferred in SIBO because they don't permanently colonize. Direct trial data in SIBO is limited; use under clinician supervision.

Drug and nutrient interactions

• Antibiotics — spores tolerate most antibacterial drugs; separate by 2 hours.
• Anticoagulants — natto consumption (not capsule probiotics) provides MK-7 vitamin K2 that can interact with warfarin; capsule B. subtilis probiotics do not deliver clinically meaningful K2.
• Immunosuppressants — theoretical concern for live-bacteria probiotics; discuss with prescriber.
• Acid suppression — spores are unaffected.
• Prebiotic fibers — synergistic.

Use our interaction checker for additional combinations.

Who might benefit — and who shouldn't bother

Frequently asked questions

Related ingredients and articles